Four months after reporting success in two rheumatoid arthritis trials with developmental partner Galapagos NV, Gilead Sciences Inc. is strengthening that partnership with a 10-year global research and development collaboration worth more than $5 billion. Gilead is also increasing the company’s stake in Galapagos.
Gilead Sciences announced that a path forward was established to submit a New Drug Application in 2019 for the investigational oral, selective JAK1 inhibitor filgotinib as a rheumatoid arthritis treatment.
New Subcutaneous Formulation of Celltrion Healthcare’s Biosimilar CT-P13 Shows Positive Results for Treatment of Rheumatoid Arthritis
Annual European Congress of Rheumatology (EULAR 2019), Autoimmune Diseases, Biosimilars, Blockbusters, Clinical Data, Monoclonal Antibodies, R&D, Rheumatoid Arthritis (RA)Celltrion Healthcare presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with rheumatoid arthritis during the treatment period of one year.
Shares in Galapagos surged nearly 16 percent after the company reported positive results from several safety and efficacy trials of the Belgian drugmaker’s rheumatoid arthritis drug filgotinib.